STOCK TITAN

Agilent Technologies Inc. - A STOCK NEWS

Welcome to our dedicated news page for Agilent Technologies (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Agilent Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Agilent Technologies's position in the market.

Rhea-AI Summary
Agilent Technologies Inc. (NYSE: A) CEO and CFO to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.55%
Tags
conferences
-
Rhea-AI Summary
Agilent Technologies Inc. (NYSE: A) has been recognized by the World Economic Forum as a Global Lighthouse for its manufacturing facility in Waldbronn, Germany. The facility is lauded for its innovative use of Fourth Industrial Revolution technologies, making it a model of smart manufacturing. Agilent is one of only 153 facilities worldwide to receive this distinction, and the only analytical and clinical laboratory technology company to be recognized.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.16%
Tags
none
-
Rhea-AI Summary
Agilent Technologies Inc. (NYSE: A) announced that the Agilent Resolve Handheld Raman Spectrometer has been recognized for excellence as a tool for emergency responders by the UK’s National CBRN Centre and the US’ Department of Homeland Security.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
none
Rhea-AI Summary
Agilent Technologies Inc. (NYSE: A) introduces water immersion and new confocal spinning disk technology to the BioTek Cytation C10 confocal imaging reader. These features enhance image quality for live-cell and 3D applications, reducing deleterious effects on live-cell samples and improving clarity for thicker samples such as tissues and 3-D spheroids.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
none
-
Rhea-AI Summary
Agilent Technologies Inc. (NYSE: A) reported revenue of $1.69 billion for Q4 2023, down 8.7% reported and 9.7% core(1) from Q4 2022. GAAP net income was $475 million; EPS was $1.62, up 32% from Q4 2022. Full fiscal year 2023 revenue was $6.83 billion, flat on a reported basis and up 1.5% core(1) year-over-year. For fiscal year 2024, revenue is expected between $6.71 billion to $6.81 billion, and non-GAAP EPS in the range of $5.44 to $5.55 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.72%
Tags
-
Rhea-AI Summary
Agilent Technologies Inc. (NYSE: A) to present at Evercore ISI HealthCONx conference on Nov. 29. President and CEO, Mike McMullen, and CFO, Bob McMahon, will lead the virtual session. The webcast will be available on Agilent's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
conferences
Rhea-AI Summary
Agilent Technologies Inc. (NYSE: A) Increases Quarterly Dividend by 5% to 23.6 Cents Per Share
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
dividends
-
Rhea-AI Summary
Agilent Technologies Inc. (NYSE: A) has received FDA approval for PD-L1 IHC 22C3 pharmDx as a diagnostic tool to identify patients with Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma eligible for treatment with KEYTRUDA® (pembrolizumab). This marks the sixth cancer type for which PD-L1 IHC 22C3 pharmDx has gained FDA approval, highlighting Agilent's leadership in developing companion diagnostics for anti-PD-1 therapies. PD-L1 IHC 22C3 pharmDx also aids in identifying patients with non-small cell lung cancer, esophageal squamous cell carcinoma, cervical cancer, head and neck squamous cell carcinoma, and triple-negative breast cancer suitable for treatment with KEYTRUDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.86%
Tags
-
Rhea-AI Summary
Agilent Technologies Inc. (NYSE: A) announces Jennifer Field, an Oregon State University researcher, as the recipient of the Agilent Thought Leader Award for her pioneering work with organic micropollutants and PFAS. Dr. Field's research focuses on the quantitative analysis of PFAS compounds, known as 'forever chemicals', and their environmental implications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
none
Rhea-AI Summary
Tele2 AB (NASDAQ: TEL2 A) and (NASDAQ: TEL2 B) in partnership with Nokia, announces the delivery of a 5G private mobile network to AirForestry for controlling electric drones used in forest thinning. The pilot project, running in 2024, aims to introduce the solution into commercial forestry operations. The technology promises to revolutionize forest harvesting, offering efficient and sustainable solutions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.04%
Tags
none
Agilent Technologies Inc.

NYSE:A

A Rankings

A Stock Data

40.09B
291.94M
0.28%
93.13%
1.35%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
US
Santa Clara

About A

analytical scientists and clinical researchers worldwide rely on agilent to help fulfill their most complex laboratory demands. our instruments, software, services and consumables address the full range of scientific and laboratory management needs—so our customers can do what they do best: improve the world around us. whether a laboratory is engaged in environmental testing, academic research, medical diagnostics, pharmaceuticals, petrochemicals or food testing, agilent provides laboratory solutions to meet their full spectrum of needs. we work closely with customers to help address global trends that impact human health and the environment, and to anticipate future scientific needs. our solutions improve the efficiency of the entire laboratory, from sample prep to data interpretation and management. customers trust agilent for solutions that enable insights...for a better world.